- Published on
Infectious Disease and Microbiology – Diverticulitis
Diverticulitis is an inflammatory condition of a diverticulum, which is a pouch formed by herniation of the mucosal layer through a weak point in the muscular wall of the gastrointestinal tract. While diverticula can occur throughout the GI tract, they are most commonly found in the colon, particularly where the vasa recta penetrate the bowel wall. The presence of diverticula without inflammation is referred to as diverticulosis or diverticular disease, whereas diverticulitis specifically indicates inflammation and possible infection.
The condition is more prevalent in Western populations and increases significantly with age, affecting fewer than 5% of individuals under 40 years old but up to 65–80% of those over 70. It accounts for more than 130,000 hospital admissions annually in the United States. Both males and females are affected equally. In Western countries, diverticulitis typically involves the descending and sigmoid colon, whereas right-sided disease is more common in Asian populations.
Risk factors include a low-fiber diet, which leads to decreased stool bulk and increased intraluminal pressure, obesity, sedentary lifestyle, and immunosuppression (e.g., organ transplant recipients). The underlying mechanism involves increased pressure within the colon at weak points, leading to formation of diverticula. Subsequent pressure and irritation can result in inflammation, microperforations, or infection by polymicrobial flora, particularly anaerobes and gram-negative bacteria. Complicated diverticulitis may involve abscess formation, peritonitis, or fistula development and is classified using Hinchey’s staging system.
Clinically, diverticulitis presents with variable severity. Common symptoms include low-grade fever, abdominal pain that often starts in the epigastric region and localizes to the left lower quadrant, and changes in bowel habits such as constipation or diarrhea. In severe cases, perforation may lead to peritoneal signs like guarding and rebound tenderness. Patients with fistula formation may report pneumaturia, fecaluria, or recurrent urinary tract infections.
On physical examination, tenderness is usually localized to the left lower quadrant, sometimes accompanied by signs of peritoneal irritation. A tender mass may be palpable on rectal examination if inflammation is adjacent to the rectum. Mild rectal bleeding may occur but is rarely significant.
Diagnosis is supported by laboratory findings such as leukocytosis and confirmed primarily through imaging. CT scanning is the most reliable diagnostic modality, with high sensitivity and specificity, demonstrating findings such as bowel wall thickening, pericolic fat inflammation, diverticula, and abscess formation. Ultrasound may be used but is more operator-dependent. Endoscopy is generally avoided during the acute phase due to risk of perforation.
Management includes antibiotic therapy targeting anaerobic and gram-negative organisms. Common regimens include ciprofloxacin plus metronidazole, trimethoprim-sulfamethoxazole plus metronidazole, or amoxicillin-clavulanate for 7–10 days. Mild cases can often be managed outpatient, while severe cases or those unable to tolerate oral intake require hospitalization and intravenous therapy. Surgical intervention may be necessary for complications such as abscesses, perforation, or peritonitis. Percutaneous drainage may be used for larger abscesses, and elective surgery may be considered after recovery to prevent recurrence.
After resolution of the acute episode, patients are advised to adopt a high-fiber diet to reduce recurrence risk. Colonoscopy is recommended to exclude underlying malignancy. Although many patients recover fully, recurrence is common, and a subset will require surgical management.
Prognosis depends on disease severity, with mortality rates increasing in advanced stages of disease. Potential complications include perforation, abscess formation, fistula development, bowel obstruction, sepsis, and rarely pylephlebitis or hepatic abscess.
Diverticulitis is an inflammatory condition of a diverticulum, which is a pouch formed by herniation of the mucosal layer through a weak point in the muscular wall of the gastrointestinal tract. While diverticula can occur throughout the GI tract, they are most commonly found in the colon, particularly where the vasa recta penetrate the bowel wall. The presence of diverticula without inflammation is referred to as diverticulosis or diverticular disease, whereas diverticulitis specifically indicates inflammation and possible infection.
The condition is more prevalent in Western populations and increases significantly with age, affecting fewer than 5% of individuals under 40 years old but up to 65–80% of those over 70. It accounts for more than 130,000 hospital admissions annually in the United States. Both males and females are affected equally. In Western countries, diverticulitis typically involves the descending and sigmoid colon, whereas right-sided disease is more common in Asian populations.
Risk factors include a low-fiber diet, which leads to decreased stool bulk and increased intraluminal pressure, obesity, sedentary lifestyle, and immunosuppression (e.g., organ transplant recipients). The underlying mechanism involves increased pressure within the colon at weak points, leading to formation of diverticula. Subsequent pressure and irritation can result in inflammation, microperforations, or infection by polymicrobial flora, particularly anaerobes and gram-negative bacteria. Complicated diverticulitis may involve abscess formation, peritonitis, or fistula development and is classified using Hinchey’s staging system.
Clinically, diverticulitis presents with variable severity. Common symptoms include low-grade fever, abdominal pain that often starts in the epigastric region and localizes to the left lower quadrant, and changes in bowel habits such as constipation or diarrhea. In severe cases, perforation may lead to peritoneal signs like guarding and rebound tenderness. Patients with fistula formation may report pneumaturia, fecaluria, or recurrent urinary tract infections.
On physical examination, tenderness is usually localized to the left lower quadrant, sometimes accompanied by signs of peritoneal irritation. A tender mass may be palpable on rectal examination if inflammation is adjacent to the rectum. Mild rectal bleeding may occur but is rarely significant.
Diagnosis is supported by laboratory findings such as leukocytosis and confirmed primarily through imaging. CT scanning is the most reliable diagnostic modality, with high sensitivity and specificity, demonstrating findings such as bowel wall thickening, pericolic fat inflammation, diverticula, and abscess formation. Ultrasound may be used but is more operator-dependent. Endoscopy is generally avoided during the acute phase due to risk of perforation.
Management includes antibiotic therapy targeting anaerobic and gram-negative organisms. Common regimens include ciprofloxacin plus metronidazole, trimethoprim-sulfamethoxazole plus metronidazole, or amoxicillin-clavulanate for 7–10 days. Mild cases can often be managed outpatient, while severe cases or those unable to tolerate oral intake require hospitalization and intravenous therapy. Surgical intervention may be necessary for complications such as abscesses, perforation, or peritonitis. Percutaneous drainage may be used for larger abscesses, and elective surgery may be considered after recovery to prevent recurrence.
After resolution of the acute episode, patients are advised to adopt a high-fiber diet to reduce recurrence risk. Colonoscopy is recommended to exclude underlying malignancy. Although many patients recover fully, recurrence is common, and a subset will require surgical management.
Prognosis depends on disease severity, with mortality rates increasing in advanced stages of disease. Potential complications include perforation, abscess formation, fistula development, bowel obstruction, sepsis, and rarely pylephlebitis or hepatic abscess.
- Published on
Infectious Disease and Microbiology – E. coli Infections
Escherichia coli are Gram-negative, rod-shaped bacteria that are part of the normal intestinal flora but can also cause a wide range of infections. They are among the most important pathogens in both community-acquired and hospital-acquired infections.
Epidemiologically, E. coli is the leading cause of nosocomial bacteremia and is responsible for more than 80% of acute uncomplicated urinary tract infections in young women. It is also a major cause of traveler’s diarrhea, typically acquired via the fecal–oral route through contaminated food or water, especially in tropical and subtropical regions. Urinary tract infections often occur due to colonization of the periurethral area followed by ascending infection. Risk factors in women include sexual activity and use of spermicides or diaphragms. In men, risks include lack of circumcision, anal intercourse, and exposure to colonized partners. Immunocompromised individuals, including those with HIV (especially CD4 <200), are also at increased risk.
Additional risk factors include anatomical abnormalities such as urinary obstruction or stones, immunosuppression (e.g., diabetes, malignancy, steroid use), and certain host susceptibility factors such as inability to secrete blood group antigens, which facilitates bacterial adherence. Preventive strategies include careful use of antibiotic prophylaxis in selected travelers and avoiding unnecessary screening for asymptomatic bacteriuria except in specific groups such as pregnant women.
The pathophysiology of E. coli infections is based on its ability to adhere to host cells and produce toxins. Different strains have distinct pathogenic mechanisms. Enterotoxigenic E. coli (ETEC) produces toxins that increase cyclic nucleotide levels, leading to increased chloride secretion and watery diarrhea. Enteropathogenic strains disrupt intestinal mucosa, especially in children. Enteroinvasive strains invade intestinal cells, causing inflammatory diarrhea. Enterohemorrhagic E. coli (EHEC), such as O157:H7, produces Shiga toxin and can cause hemorrhagic colitis and hemolytic–uremic syndrome, often associated with contaminated beef or dairy products. Enteroaggregative strains are linked to persistent diarrhea, particularly in travelers and immunocompromised patients.
Uropathogenic E. coli strains possess specific virulence factors, including pili that allow adherence to uroepithelial cells, leading to infections ranging from cystitis to pyelonephritis and even septicemia. Beyond the urinary and gastrointestinal systems, E. coli can cause intra-abdominal infections such as abscesses, cholecystitis, and cholangitis. It is also associated with serious conditions including meningitis in neonates, as well as endocarditis, pneumonia, osteomyelitis, septic arthritis, and other systemic infections.
Diagnosis is confirmed by isolating E. coli from normally sterile sites such as blood, cerebrospinal fluid, or bile. In diarrheal illness, specialized testing such as PCR or toxin detection may be required to identify specific pathogenic strains. Imaging studies like abdominal CT or ultrasound may help identify complications such as abscesses or hepatobiliary infections. The differential diagnosis depends on the clinical presentation and includes other bacterial causes such as Campylobacter, Salmonella, and Shigella, particularly in cases of bloody diarrhea.
Treatment depends on the type and severity of infection. Localized infections require both antimicrobial therapy and, when necessary, drainage of abscesses or removal of infected material. Traveler’s diarrhea is commonly treated with short courses of fluoroquinolones or trimethoprim–sulfamethoxazole, along with supportive therapy such as hydration and antidiarrheal agents. However, antibiotics are generally avoided in EHEC infections due to the risk of worsening toxin-mediated complications such as hemolytic–uremic syndrome.
Uncomplicated cystitis is treated with short courses of oral antibiotics, while pyelonephritis requires longer treatment and sometimes hospitalization for intravenous therapy. Severe infections such as bacteremia or sepsis require broad-spectrum intravenous antibiotics, including fluoroquinolones, third-generation cephalosporins, or carbapenems. Pregnant patients require specific antibiotic choices such as penicillins, cephalosporins, or nitrofurantoin.
Follow-up is important in patients with persistent bacteremia or recurrent infections, as these may indicate underlying abnormalities such as abscesses, urinary tract obstruction, or foreign bodies. Prognosis is generally good with appropriate treatment, although complications such as dehydration, septic shock, and hemolytic–uremic syndrome can occur. Severe systemic infections may be life-threatening, particularly in vulnerable populations such as those with liver disease, immunosuppression, or impaired immune function.
- Published on
Infectious Disease and Microbiology – Echinococcosis
Echinococcosis, also known as hydatid disease, is a parasitic infection caused by species of the genus Echinococcus. The most important species include Echinococcus granulosus, which causes cystic echinococcosis (CE), Echinococcus multilocularis, which causes alveolar echinococcosis (AE), and Echinococcus vogeli, which causes polycystic echinococcosis. These infections are characterized by the formation of cysts in various organs, most commonly the liver and lungs.
The disease is endemic in many parts of the world. Cystic echinococcosis is prevalent in Central Asia, South America, and North Africa, while alveolar echinococcosis is increasingly reported in Central Europe and is highly endemic in parts of China. Polycystic echinococcosis is rare and primarily found in Latin America. Transmission is closely associated with rural environments and animal husbandry practices. Humans acquire infection through contact with infected definitive hosts, typically dogs in CE and foxes or wild canids in AE, or through ingestion of food or water contaminated with parasite eggs.
Risk factors include close contact with dogs or other canines, exposure to livestock such as sheep, poor hygiene, and residence in endemic rural areas. Inadequate slaughterhouse practices and allowing dogs access to infected animal viscera perpetuate the parasite’s lifecycle. Preventive measures focus on improved hygiene, control of stray dog populations, proper disposal of animal remains, and vaccination of livestock.
After ingestion, parasite eggs hatch in the intestine, and larvae penetrate the intestinal wall to enter the bloodstream. They are carried to target organs, most commonly the liver (about 65%) and lungs (about 20%), where they develop into slowly growing cysts. These cysts may produce daughter cysts and can enlarge over time, causing pressure effects. In alveolar echinococcosis, lesions are typically infiltrative and destructive, resembling malignant tumors such as hepatocellular carcinoma and often confined to the liver.
Clinically, cystic echinococcosis is often asymptomatic and discovered incidentally. Symptoms arise due to mass effect depending on the organ involved. Complications include cyst rupture, which may lead to anaphylactic shock, dissemination of infection, or communication with adjacent structures such as the biliary tract or bronchial tree. Physical examination findings are often minimal, though hepatomegaly or a palpable mass may be present.
Diagnosis relies primarily on imaging and serology. Ultrasound is the initial modality of choice, particularly for hepatic cysts, and may reveal characteristic features such as daughter cysts, multilocular appearance, or specific signs like the “water lily” sign. CT and MRI provide further characterization. Serologic testing, typically using ELISA, supports the diagnosis, although sensitivity varies. Eosinophilia may be present but is not consistent. Cyst puncture is generally contraindicated due to the risk of anaphylaxis and parasite dissemination.
Treatment depends on the type and stage of disease. Surgical removal of cysts is the mainstay of treatment for cystic echinococcosis and is often curative. Albendazole is the primary pharmacologic therapy and is used in inoperable cases, disseminated disease, or as adjunctive therapy before and after surgery. Mebendazole is less effective, while praziquantel may be used as an adjunct in selected cases. A less invasive approach, known as PAIR (puncture, aspiration, injection, reaspiration), is used in selected cases and has shown promising results when combined with antiparasitic therapy.
Alveolar echinococcosis requires more aggressive management, often involving radical surgery combined with long-term albendazole therapy, though outcomes are less favorable compared to cystic disease. Follow-up is mainly performed using imaging to monitor cyst progression or recurrence.
Prognosis is generally excellent for cystic echinococcosis with appropriate treatment, whereas alveolar echinococcosis carries a higher mortality if untreated. Complications include cyst rupture with anaphylaxis, secondary infection, dissemination of the parasite, and in AE, progressive tissue destruction with metastatic-like spread.
Echinococcosis, also known as hydatid disease, is a parasitic infection caused by species of the genus Echinococcus. The most important species include Echinococcus granulosus, which causes cystic echinococcosis (CE), Echinococcus multilocularis, which causes alveolar echinococcosis (AE), and Echinococcus vogeli, which causes polycystic echinococcosis. These infections are characterized by the formation of cysts in various organs, most commonly the liver and lungs.
The disease is endemic in many parts of the world. Cystic echinococcosis is prevalent in Central Asia, South America, and North Africa, while alveolar echinococcosis is increasingly reported in Central Europe and is highly endemic in parts of China. Polycystic echinococcosis is rare and primarily found in Latin America. Transmission is closely associated with rural environments and animal husbandry practices. Humans acquire infection through contact with infected definitive hosts, typically dogs in CE and foxes or wild canids in AE, or through ingestion of food or water contaminated with parasite eggs.
Risk factors include close contact with dogs or other canines, exposure to livestock such as sheep, poor hygiene, and residence in endemic rural areas. Inadequate slaughterhouse practices and allowing dogs access to infected animal viscera perpetuate the parasite’s lifecycle. Preventive measures focus on improved hygiene, control of stray dog populations, proper disposal of animal remains, and vaccination of livestock.
After ingestion, parasite eggs hatch in the intestine, and larvae penetrate the intestinal wall to enter the bloodstream. They are carried to target organs, most commonly the liver (about 65%) and lungs (about 20%), where they develop into slowly growing cysts. These cysts may produce daughter cysts and can enlarge over time, causing pressure effects. In alveolar echinococcosis, lesions are typically infiltrative and destructive, resembling malignant tumors such as hepatocellular carcinoma and often confined to the liver.
Clinically, cystic echinococcosis is often asymptomatic and discovered incidentally. Symptoms arise due to mass effect depending on the organ involved. Complications include cyst rupture, which may lead to anaphylactic shock, dissemination of infection, or communication with adjacent structures such as the biliary tract or bronchial tree. Physical examination findings are often minimal, though hepatomegaly or a palpable mass may be present.
Diagnosis relies primarily on imaging and serology. Ultrasound is the initial modality of choice, particularly for hepatic cysts, and may reveal characteristic features such as daughter cysts, multilocular appearance, or specific signs like the “water lily” sign. CT and MRI provide further characterization. Serologic testing, typically using ELISA, supports the diagnosis, although sensitivity varies. Eosinophilia may be present but is not consistent. Cyst puncture is generally contraindicated due to the risk of anaphylaxis and parasite dissemination.
Treatment depends on the type and stage of disease. Surgical removal of cysts is the mainstay of treatment for cystic echinococcosis and is often curative. Albendazole is the primary pharmacologic therapy and is used in inoperable cases, disseminated disease, or as adjunctive therapy before and after surgery. Mebendazole is less effective, while praziquantel may be used as an adjunct in selected cases. A less invasive approach, known as PAIR (puncture, aspiration, injection, reaspiration), is used in selected cases and has shown promising results when combined with antiparasitic therapy.
Alveolar echinococcosis requires more aggressive management, often involving radical surgery combined with long-term albendazole therapy, though outcomes are less favorable compared to cystic disease. Follow-up is mainly performed using imaging to monitor cyst progression or recurrence.
Prognosis is generally excellent for cystic echinococcosis with appropriate treatment, whereas alveolar echinococcosis carries a higher mortality if untreated. Complications include cyst rupture with anaphylaxis, secondary infection, dissemination of the parasite, and in AE, progressive tissue destruction with metastatic-like spread.
- Published on
Infectious Disease and Microbiology – Ehrlichiosis and Anaplasmosis
Ehrlichiosis and anaplasmosis are systemic infections caused by obligate intracellular bacteria belonging to the family Anaplasmataceae, which includes the genera Ehrlichia, Anaplasma, Neorickettsia, and Wolbachia. These organisms primarily infect humans through tick bites, especially during the summer months when tick activity is highest. They target cells of the reticuloendothelial system, particularly monocytes and granulocytes, leading to a wide range of clinical manifestations. In immunocompetent individuals, the disease is often mild to moderate, presenting with nonspecific symptoms such as fever, malaise, headache, myalgias, nausea, and vomiting. However, in immunocompromised patients, including those with AIDS or on corticosteroid therapy, infections may become severe, with central nervous system involvement, multiple organ dysfunction, and even death.
Epidemiologically, ehrlichiosis and anaplasmosis are primarily reported in the United States but also occur worldwide. Human monocytic ehrlichiosis (HME), caused by Ehrlichia chaffeensis, is transmitted mainly by the tick Amblyomma americanum, particularly in the southeastern and south-central US. Human granulocytic anaplasmosis (HGA), caused by Anaplasma phagocytophilum, is transmitted by Ixodes scapularis, with most cases reported in regions such as Wisconsin, Minnesota, New England, New Jersey, and New York. Cases are also reported in parts of Europe. Subclinical infections are common, and many cases are underdiagnosed. Coinfections with other tick-borne pathogens, such as Babesia microti and Borrelia burgdorferi, may occur due to shared vectors.
Risk factors include exposure to tick-infested environments, outdoor activities in endemic areas, and immunosuppression. Prevention focuses on avoiding tick bites by wearing protective clothing, using insect repellents containing DEET, and performing thorough body checks after potential exposure. Prompt removal of ticks is essential to reduce transmission risk.
The pathophysiology involves bacterial invasion of host immune cells, where the organisms reside within membrane-bound vacuoles. Ehrlichia chaffeensis primarily infects macrophages, while Anaplasma phagocytophilum targets granulocytes. These infections lead to hematologic abnormalities such as leukopenia and thrombocytopenia, as well as systemic inflammation. If untreated, the disease can progress to severe multisystem involvement.
Clinically, symptoms usually develop about 7 days after a tick bite. Patients present with fever, malaise, headache, myalgias, nausea, and sometimes rash, which may be maculopapular or hemorrhagic. Lymphadenopathy and hepatosplenomegaly may occur. Severe cases can progress to septic shock, acute respiratory distress syndrome, and neurological complications such as seizures or coma. Human granulocytic anaplasmosis presents similarly but may lack rash unless there is coinfection with other tick-borne diseases.
Diagnosis is based on clinical suspicion supported by laboratory findings. Common laboratory abnormalities include leukopenia, thrombocytopenia, anemia, and elevated liver enzymes. Serologic testing using indirect immunofluorescence is considered the gold standard but may be negative early in the disease. Polymerase chain reaction (PCR) testing offers higher sensitivity during acute infection but requires specialized laboratories. Blood smear examination has low sensitivity. Imaging such as chest X-ray may show findings consistent with acute respiratory distress syndrome in severe cases.
The differential diagnosis includes other infectious and noninfectious conditions such as endocarditis, septicemia, vasculitis, thrombotic thrombocytopenic purpura, and other tick-borne illnesses including tularemia, babesiosis, Lyme disease, Rocky Mountain spotted fever, and murine typhus.
Treatment should be initiated promptly when the disease is suspected. Doxycycline is the first-line therapy and is effective for both ehrlichiosis and anaplasmosis, typically resulting in clinical improvement within 24–48 hours. Treatment duration is usually 7–14 days. In cases where doxycycline cannot be used, such as pregnancy, rifampin may be considered. Chloramphenicol has been used but is less reliable and may not be effective in all cases.
Follow-up is important to ensure clinical improvement, as lack of response within 48 hours should prompt reconsideration of the diagnosis. Persistent infection has been reported despite treatment, and expert consultation may be necessary in complicated cases.
Complications can be severe, particularly if untreated. These include respiratory failure, neurological involvement, acute renal failure, gastrointestinal hemorrhage, and death. Hospitalization is common, with a significant proportion of patients developing severe disease. Mortality rates are estimated at 2–5%, with higher risk in elderly and immunocompromised individuals.
- Published on
Infectious Disease And Microbiology – Empyema
Empyema is defined as the accumulation of purulent (pus-containing) fluid within the pleural cavity. It most commonly develops as a complication of bacterial pneumonia but may also arise following thoracic surgery, trauma, esophageal perforation, or subdiaphragmatic infections. In children, empyema is usually secondary to pneumonia—most often caused by Streptococcus pneumoniae—and tends to have a better prognosis than in adults, although management principles are similar. Overall, pleural effusions occur in up to 57% of pneumonia cases, but only about 1–2% progress to empyema. The condition affects individuals of all ages, with higher prevalence in the elderly and in children, and occurs more frequently in males.
Several risk factors predispose individuals to empyema, including diabetes mellitus, alcoholism, substance abuse, rheumatoid arthritis, chronic lung disease, poor dental hygiene, malignancy, and prior thoracic surgery. Conditions that increase the risk of aspiration are particularly associated with anaerobic infections. Prevention focuses on appropriate treatment of pneumonia, adherence to surgical infection control practices, and vaccination (especially pneumococcal vaccination).
The development of empyema progresses through three stages. The exudative stage involves inflammation and fluid accumulation in the pleural space. This is followed by the fibrinopurulent stage, characterized by fibrin deposition and pus formation. Finally, the organizing stage occurs, where fibroblasts proliferate and collagen is deposited, potentially leading to pleural thickening and restricted lung expansion. The causative organisms vary depending on whether the infection is community-acquired or hospital-acquired. Community-acquired empyema commonly involves streptococci, staphylococci, anaerobes, and Enterobacteriaceae, while hospital-acquired cases are more often caused by methicillin-resistant Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, enterococci, and other resistant organisms.
Clinically, patients often present with a history of pneumonia or thoracic procedures, along with symptoms such as fever, chest pain, and shortness of breath. In elderly or immunocompromised patients, symptoms may be subtle, including weight loss or anemia. On physical examination, findings may include dullness to percussion, decreased tactile fremitus, and absent breath sounds over the affected area, although small effusions may not produce obvious signs.
Diagnosis is confirmed through thoracentesis, with the presence of pus in the pleural space being definitive. Laboratory evaluation includes complete blood count and inflammatory markers such as C-reactive protein. Pleural fluid analysis is essential and typically shows low pH (<7.2), high white blood cell count, and positive Gram stain or culture. Imaging plays a key role: chest X-ray identifies pleural effusion, ultrasound helps localize fluid and guide drainage, and CT scan can distinguish empyema from lung abscess (notably showing the “split pleura” sign).
The differential diagnosis includes other causes of pleural effusion, lung abscess, and pneumonia. Management requires prompt initiation of antimicrobial therapy along with drainage of the infected fluid, usually via chest tube. Antibiotic regimens differ based on whether the infection is community- or hospital-acquired and should cover likely pathogens, including anaerobes and resistant organisms where appropriate. Adjunctive treatments include adequate hydration, nutritional support, and, in some cases, intrapleural fibrinolytic therapy to improve drainage.
In cases where drainage is incomplete or complications arise, surgical intervention may be necessary. Options include video-assisted thoracoscopic surgery (VATS), thoracotomy with decortication, or other open surgical procedures. Most patients require hospitalization for intravenous antibiotics and monitoring. Follow-up involves continued antibiotic therapy for 2–4 weeks, monitoring inflammatory markers, and ensuring adequate drainage. Chest tubes are typically removed once drainage decreases and fluid clears.
The prognosis of empyema varies depending on patient factors and timeliness of treatment. While many patients recover with appropriate management, mortality rates range from 7% to 33% within one year and may exceed 50% in patients with significant comorbidities. Complications include pleural thickening, pulmonary fibrosis, pneumothorax, bronchopleural fistula, respiratory failure, septic shock, and, in rare cases, empyema necessitatis.
- Published on
Infectious Disease And Microbiology – Encephalitis
Encephalitis is an inflammation of the brain parenchyma that leads to neurological dysfunction and is most commonly caused by infections. These infections may be viral, bacterial, fungal, or protozoal, with viruses being the most frequent cause. The condition typically arises when pathogens spread to the central nervous system via the bloodstream, although some, such as rabies, travel through peripheral nerves. Clinically, encephalitis often presents with fever, headache, confusion, and altered mental status, and may also involve seizures or focal neurological deficits.
Epidemiologically, encephalitis affects both extremes of age, particularly the very young and the elderly. Viral encephalitis is the most common form, with an annual incidence of approximately 3.5–7.4 cases per 100,000 people, accounting for around 20,000 new cases each year. In the United States, herpes simplex virus (HSV) is the leading identifiable cause, responsible for about 10% of all cases. In neonates, HSV-2 is the most common cause and is typically acquired during delivery. In many cases—up to 75%—no specific causative agent is identified.
Risk factors for encephalitis include age, immune status, seasonal exposure, and environmental or travel-related exposures. Arboviral infections are more common during summer and fall, while HSV infections occur year-round. Exposure to mosquitoes, ticks, animals, or contaminated water sources increases risk. Preventive strategies include avoiding insect bites, implementing vector control measures, and vaccination against preventable viral causes such as measles, mumps, rubella, polio, varicella, and Japanese encephalitis.
The pathophysiology varies depending on the causative organism but generally involves viremia followed by invasion of the central nervous system. This leads to inflammation, neuronal injury, and sometimes necrosis. In HSV encephalitis, the temporal lobes are commonly affected, whereas other viruses may target different brain regions such as the brainstem or gray matter.
Etiologically, encephalitis has a broad range of causes. Viral pathogens include herpesviruses (HSV, CMV, VZV), arboviruses (e.g., West Nile virus, Japanese encephalitis virus), enteroviruses, rabies virus, and HIV. Bacterial causes include Listeria monocytogenes, Mycobacterium tuberculosis, and Mycoplasma. Other causes include rickettsial organisms, spirochetes such as Borrelia burgdorferi, fungi like Cryptococcus neoformans, and protozoa such as Toxoplasma gondii and Naegleria fowleri. Helminths such as Taenia solium may also be implicated.
Diagnosis relies heavily on clinical suspicion, supported by history and examination. Important historical clues include recent travel, insect or animal exposure, and immune status. Physical examination focuses on neurological findings, though skin examination may reveal rashes that help identify specific etiologies. Because encephalitis may overlap clinically with meningitis, distinguishing between the two can be challenging.
Laboratory evaluation includes cerebrospinal fluid (CSF) analysis obtained via lumbar puncture, which typically shows lymphocytic pleocytosis, elevated protein, and normal glucose in viral cases. PCR testing of CSF is essential for identifying viral pathogens such as HSV, CMV, and VZV. Additional tests may include serology, blood cultures, and pathogen-specific assays depending on clinical suspicion. Imaging is critical, with brain MRI being the gold standard; characteristic findings such as temporal lobe involvement suggest HSV encephalitis. CT scanning is useful when MRI is unavailable or to rule out contraindications to lumbar puncture.
The differential diagnosis is broad and includes meningitis, brain abscess, encephalopathy, acute disseminated encephalomyelitis, metabolic disorders, vasculitis, and drug-induced aseptic meningitis. Management requires prompt empiric therapy. Until bacterial meningitis is excluded, patients should receive broad antimicrobial coverage along with antiviral therapy. Intravenous acyclovir is the treatment of choice for suspected HSV encephalitis and should be started immediately. Other antiviral or antimicrobial treatments depend on the identified pathogen, and adjunctive therapies such as antiretroviral treatment may be required in HIV-related cases.
Patients with encephalitis require hospitalization, often with intensive care monitoring. Supportive care includes adequate hydration, especially during acyclovir therapy to prevent renal toxicity. Close monitoring is essential, as recovery may be prolonged and incomplete.
The prognosis of encephalitis varies widely depending on the causative organism and timeliness of treatment. HSV encephalitis, if untreated, carries a mortality rate of up to 70%, but early treatment reduces mortality to 6–19%. However, many survivors experience long-term neurological deficits. Younger patients tend to have better outcomes.
Complications of encephalitis include seizures, permanent neurological impairment, relapse (particularly in HSV infection), and death. Long-term follow-up may involve neuropsychological assessment to evaluate cognitive and functional outcomes.
Encephalitis is an inflammation of the brain parenchyma that leads to neurological dysfunction and is most commonly caused by infections. These infections may be viral, bacterial, fungal, or protozoal, with viruses being the most frequent cause. The condition typically arises when pathogens spread to the central nervous system via the bloodstream, although some, such as rabies, travel through peripheral nerves. Clinically, encephalitis often presents with fever, headache, confusion, and altered mental status, and may also involve seizures or focal neurological deficits.
Epidemiologically, encephalitis affects both extremes of age, particularly the very young and the elderly. Viral encephalitis is the most common form, with an annual incidence of approximately 3.5–7.4 cases per 100,000 people, accounting for around 20,000 new cases each year. In the United States, herpes simplex virus (HSV) is the leading identifiable cause, responsible for about 10% of all cases. In neonates, HSV-2 is the most common cause and is typically acquired during delivery. In many cases—up to 75%—no specific causative agent is identified.
Risk factors for encephalitis include age, immune status, seasonal exposure, and environmental or travel-related exposures. Arboviral infections are more common during summer and fall, while HSV infections occur year-round. Exposure to mosquitoes, ticks, animals, or contaminated water sources increases risk. Preventive strategies include avoiding insect bites, implementing vector control measures, and vaccination against preventable viral causes such as measles, mumps, rubella, polio, varicella, and Japanese encephalitis.
The pathophysiology varies depending on the causative organism but generally involves viremia followed by invasion of the central nervous system. This leads to inflammation, neuronal injury, and sometimes necrosis. In HSV encephalitis, the temporal lobes are commonly affected, whereas other viruses may target different brain regions such as the brainstem or gray matter.
Etiologically, encephalitis has a broad range of causes. Viral pathogens include herpesviruses (HSV, CMV, VZV), arboviruses (e.g., West Nile virus, Japanese encephalitis virus), enteroviruses, rabies virus, and HIV. Bacterial causes include Listeria monocytogenes, Mycobacterium tuberculosis, and Mycoplasma. Other causes include rickettsial organisms, spirochetes such as Borrelia burgdorferi, fungi like Cryptococcus neoformans, and protozoa such as Toxoplasma gondii and Naegleria fowleri. Helminths such as Taenia solium may also be implicated.
Diagnosis relies heavily on clinical suspicion, supported by history and examination. Important historical clues include recent travel, insect or animal exposure, and immune status. Physical examination focuses on neurological findings, though skin examination may reveal rashes that help identify specific etiologies. Because encephalitis may overlap clinically with meningitis, distinguishing between the two can be challenging.
Laboratory evaluation includes cerebrospinal fluid (CSF) analysis obtained via lumbar puncture, which typically shows lymphocytic pleocytosis, elevated protein, and normal glucose in viral cases. PCR testing of CSF is essential for identifying viral pathogens such as HSV, CMV, and VZV. Additional tests may include serology, blood cultures, and pathogen-specific assays depending on clinical suspicion. Imaging is critical, with brain MRI being the gold standard; characteristic findings such as temporal lobe involvement suggest HSV encephalitis. CT scanning is useful when MRI is unavailable or to rule out contraindications to lumbar puncture.
The differential diagnosis is broad and includes meningitis, brain abscess, encephalopathy, acute disseminated encephalomyelitis, metabolic disorders, vasculitis, and drug-induced aseptic meningitis. Management requires prompt empiric therapy. Until bacterial meningitis is excluded, patients should receive broad antimicrobial coverage along with antiviral therapy. Intravenous acyclovir is the treatment of choice for suspected HSV encephalitis and should be started immediately. Other antiviral or antimicrobial treatments depend on the identified pathogen, and adjunctive therapies such as antiretroviral treatment may be required in HIV-related cases.
Patients with encephalitis require hospitalization, often with intensive care monitoring. Supportive care includes adequate hydration, especially during acyclovir therapy to prevent renal toxicity. Close monitoring is essential, as recovery may be prolonged and incomplete.
The prognosis of encephalitis varies widely depending on the causative organism and timeliness of treatment. HSV encephalitis, if untreated, carries a mortality rate of up to 70%, but early treatment reduces mortality to 6–19%. However, many survivors experience long-term neurological deficits. Younger patients tend to have better outcomes.
Complications of encephalitis include seizures, permanent neurological impairment, relapse (particularly in HSV infection), and death. Long-term follow-up may involve neuropsychological assessment to evaluate cognitive and functional outcomes.
- Published on
Infectious Disease And Microbiology – Endocarditis (Native Valves)
Endocarditis is an infection of the endocardial surface of the heart, most commonly involving the heart valves. It is typically caused by bacteria, though fungi and, rarely, organisms such as chlamydiae or rickettsiae may be responsible. In native valve infective endocarditis (NVIE), the mitral valve is most frequently affected, followed by the aortic valve. The tricuspid valve is more commonly involved in individuals who use intravenous drugs, while pulmonic valve involvement is rare. In some cases, multiple valves may be infected simultaneously.
The incidence of NVIE ranges from approximately 1.7 to 6.2 cases per 100,000 person-years, but is significantly higher among intravenous drug users. Risk factors include intravenous drug use, prior history of endocarditis, chronic intravascular access, implanted cardiac devices, congenital heart disease, bicuspid aortic valve, rheumatic heart disease, and degenerative valvular disease. Preventive strategies include antibiotic prophylaxis for high-risk individuals—such as those with prosthetic valves, prior endocarditis, certain congenital heart diseases, or cardiac transplant recipients with valvulopathy—especially before dental procedures involving manipulation of the gingiva or oral mucosa.
The most common causative organisms are Gram-positive bacteria, with Staphylococcus aureus now being the leading cause of NVIE. Other important pathogens include viridans group streptococci, Streptococcus bovis, enterococci, coagulase-negative staphylococci, and the HACEK group of organisms. Fungal infections account for a smaller proportion of cases. Approximately 10% of cases are culture-negative, often due to prior antibiotic use or infection with fastidious organisms such as Bartonella or Coxiella burnetii.
Clinically, NVIE presents with a wide range of symptoms resulting from valvular infection, embolic phenomena, metastatic infection, and immune complex deposition. Fever is present in over 90% of patients, along with nonspecific symptoms such as malaise, fatigue, weight loss, and chills. The modified Duke criteria are widely used for diagnosis and incorporate clinical, microbiological, and echocardiographic findings. Major criteria include positive blood cultures with typical organisms and evidence of endocardial involvement on echocardiography, while minor criteria include fever, predisposing conditions, vascular and immunologic phenomena, and less specific microbiologic evidence.
On physical examination, a new or changing heart murmur is found in the majority of patients. Other findings may include petechiae, splinter hemorrhages, Osler nodes, Janeway lesions, and Roth spots, although these are less common. A thorough examination is necessary to detect complications such as embolic events or metastatic infections.
Diagnosis requires prompt laboratory and imaging evaluation. Blood cultures are critical and should be obtained before starting antibiotics, with at least three sets drawn within the first 24 hours. Most cases can be diagnosed based on positive blood cultures. Laboratory findings often include leukocytosis, elevated inflammatory markers, and abnormalities on urinalysis such as hematuria or proteinuria. In cases of culture-negative endocarditis, serologic testing for atypical organisms may be necessary.
Echocardiography is the imaging modality of choice. Transthoracic echocardiography (TTE) is often used initially, but transesophageal echocardiography (TEE) is more sensitive and is preferred when clinical suspicion is high or when TTE results are inconclusive. Imaging may reveal vegetations, abscesses, or valvular dysfunction. Additional imaging studies may be required to evaluate for embolic complications or abscess formation in other organs.
Treatment involves prolonged intravenous bactericidal antibiotic therapy tailored to the causative organism and its antimicrobial susceptibilities. Empiric therapy is initiated based on clinical suspicion and risk factors. Common regimens include penicillin or ceftriaxone for streptococcal infections, ampicillin with gentamicin for enterococci, and nafcillin or vancomycin for Staphylococcus aureus. Therapy typically lasts several weeks to ensure eradication of infection within vegetations.
Surgical intervention is required in approximately 30–50% of cases and is considered in patients with heart failure, uncontrolled infection, large vegetations with recurrent emboli, or complications such as abscess formation. Management often requires a multidisciplinary approach involving cardiology, infectious diseases, and cardiac surgery teams.
Patients with endocarditis require hospitalization for initiation of treatment and close monitoring. Follow-up includes repeated blood cultures to confirm clearance of infection, monitoring for complications, and echocardiography to assess cardiac function after treatment. Patient education is important, particularly regarding oral hygiene and prevention of future infections.
The prognosis of NVIE depends on multiple factors, including the causative organism, patient comorbidities, and presence of complications. Mortality remains significant, with rates approaching 40% at one year. Poor prognostic factors include heart failure, infection with Staphylococcus aureus, older age, immunosuppression, and extension of infection beyond the valve. Complications include heart failure, stroke, systemic emboli, renal infarction, glomerulonephritis, mycotic aneurysms, and metastatic infections such as splenic abscess or meningitis.
Endocarditis is an infection of the endocardial surface of the heart, most commonly involving the heart valves. It is typically caused by bacteria, though fungi and, rarely, organisms such as chlamydiae or rickettsiae may be responsible. In native valve infective endocarditis (NVIE), the mitral valve is most frequently affected, followed by the aortic valve. The tricuspid valve is more commonly involved in individuals who use intravenous drugs, while pulmonic valve involvement is rare. In some cases, multiple valves may be infected simultaneously.
The incidence of NVIE ranges from approximately 1.7 to 6.2 cases per 100,000 person-years, but is significantly higher among intravenous drug users. Risk factors include intravenous drug use, prior history of endocarditis, chronic intravascular access, implanted cardiac devices, congenital heart disease, bicuspid aortic valve, rheumatic heart disease, and degenerative valvular disease. Preventive strategies include antibiotic prophylaxis for high-risk individuals—such as those with prosthetic valves, prior endocarditis, certain congenital heart diseases, or cardiac transplant recipients with valvulopathy—especially before dental procedures involving manipulation of the gingiva or oral mucosa.
The most common causative organisms are Gram-positive bacteria, with Staphylococcus aureus now being the leading cause of NVIE. Other important pathogens include viridans group streptococci, Streptococcus bovis, enterococci, coagulase-negative staphylococci, and the HACEK group of organisms. Fungal infections account for a smaller proportion of cases. Approximately 10% of cases are culture-negative, often due to prior antibiotic use or infection with fastidious organisms such as Bartonella or Coxiella burnetii.
Clinically, NVIE presents with a wide range of symptoms resulting from valvular infection, embolic phenomena, metastatic infection, and immune complex deposition. Fever is present in over 90% of patients, along with nonspecific symptoms such as malaise, fatigue, weight loss, and chills. The modified Duke criteria are widely used for diagnosis and incorporate clinical, microbiological, and echocardiographic findings. Major criteria include positive blood cultures with typical organisms and evidence of endocardial involvement on echocardiography, while minor criteria include fever, predisposing conditions, vascular and immunologic phenomena, and less specific microbiologic evidence.
On physical examination, a new or changing heart murmur is found in the majority of patients. Other findings may include petechiae, splinter hemorrhages, Osler nodes, Janeway lesions, and Roth spots, although these are less common. A thorough examination is necessary to detect complications such as embolic events or metastatic infections.
Diagnosis requires prompt laboratory and imaging evaluation. Blood cultures are critical and should be obtained before starting antibiotics, with at least three sets drawn within the first 24 hours. Most cases can be diagnosed based on positive blood cultures. Laboratory findings often include leukocytosis, elevated inflammatory markers, and abnormalities on urinalysis such as hematuria or proteinuria. In cases of culture-negative endocarditis, serologic testing for atypical organisms may be necessary.
Echocardiography is the imaging modality of choice. Transthoracic echocardiography (TTE) is often used initially, but transesophageal echocardiography (TEE) is more sensitive and is preferred when clinical suspicion is high or when TTE results are inconclusive. Imaging may reveal vegetations, abscesses, or valvular dysfunction. Additional imaging studies may be required to evaluate for embolic complications or abscess formation in other organs.
Treatment involves prolonged intravenous bactericidal antibiotic therapy tailored to the causative organism and its antimicrobial susceptibilities. Empiric therapy is initiated based on clinical suspicion and risk factors. Common regimens include penicillin or ceftriaxone for streptococcal infections, ampicillin with gentamicin for enterococci, and nafcillin or vancomycin for Staphylococcus aureus. Therapy typically lasts several weeks to ensure eradication of infection within vegetations.
Surgical intervention is required in approximately 30–50% of cases and is considered in patients with heart failure, uncontrolled infection, large vegetations with recurrent emboli, or complications such as abscess formation. Management often requires a multidisciplinary approach involving cardiology, infectious diseases, and cardiac surgery teams.
Patients with endocarditis require hospitalization for initiation of treatment and close monitoring. Follow-up includes repeated blood cultures to confirm clearance of infection, monitoring for complications, and echocardiography to assess cardiac function after treatment. Patient education is important, particularly regarding oral hygiene and prevention of future infections.
The prognosis of NVIE depends on multiple factors, including the causative organism, patient comorbidities, and presence of complications. Mortality remains significant, with rates approaching 40% at one year. Poor prognostic factors include heart failure, infection with Staphylococcus aureus, older age, immunosuppression, and extension of infection beyond the valve. Complications include heart failure, stroke, systemic emboli, renal infarction, glomerulonephritis, mycotic aneurysms, and metastatic infections such as splenic abscess or meningitis.
- Published on
Infectious Disease and Microbiology: Fungal Infections of the Hair, Skin, and Nails (Dermatophytosis / Tinea)
Fungal infections of the hair, skin, and nails—collectively known as dermatophytosis or tinea—are common infectious diseases affecting keratinized tissues. These infections are caused by dermatophyte fungi that invade the superficial layers of the skin, hair, or nails through enzymes such as keratinases. They are classified based on the site of infection, including tinea pedis (feet), tinea corporis (body), tinea cruris (groin), tinea capitis (scalp), and onychomycosis (nails). These infections occur worldwide and are particularly common in hot and humid climates.
Epidemiologically, dermatophytosis affects different populations depending on the type. Tinea capitis is most common in children, while tinea pedis is more frequently seen in young adult males. Onychomycosis is the most common nail disorder in adults. Risk factors include excessive moisture, tight clothing, poor hygiene, diabetes mellitus, obesity, and immunosuppression. Transmission occurs through direct contact with infected individuals, animals, or contaminated objects such as towels, footwear, and communal shower surfaces.
The pathophysiology involves fungal invasion of keratinized structures such as the stratum corneum, hair shafts, and nail beds. The fungi proliferate outward, producing characteristic ring-shaped lesions with central clearing in skin infections. In scalp infections, the hair becomes brittle and breaks, resulting in patches of alopecia. Nail infections lead to thickened, discolored, and brittle nails. The host immune response contributes to inflammation, scaling, and itching, while also attempting to contain the infection.
Clinically, the presentation varies according to the site involved. Tinea pedis typically presents with itching, scaling, and fissuring between the toes. Tinea corporis manifests as circular, erythematous, scaly lesions with raised borders. Tinea cruris causes an itchy rash in the groin area. Tinea capitis presents with scalp scaling, hair loss, and sometimes pustules. Onychomycosis results in thickened, discolored, and brittle nails. Secondary bacterial infection may complicate some cases, especially in tinea pedis.
Diagnosis is usually established by microscopic examination of skin scrapings, hair, or nail samples using potassium hydroxide preparation. Fungal cultures on specialized media can confirm the diagnosis, and Wood’s lamp examination may assist in detecting certain species. Advanced techniques such as polymerase chain reaction may be used in specialized settings.
Treatment depends on the severity and location of the infection. Most superficial infections respond to topical antifungal agents such as Terbinafine, tolnaftate, or undecylenic acid. Oral antifungal therapy, including Griseofulvin or Ketoconazole, is required for more extensive disease, scalp involvement, or nail infections. Onychomycosis typically requires prolonged treatment. Preventive measures such as maintaining hygiene, keeping skin dry, avoiding sharing personal items, and using protective footwear in communal areas are important to prevent recurrence.
The prognosis is generally excellent with appropriate treatment, although recurrence is common if predisposing factors persist. Complications are uncommon but may include secondary bacterial infections, chronic disease, and, in severe scalp infections, permanent hair loss. Early diagnosis and adherence to therapy are essential for successful management.
- Published on
Infectious Disease And Microbiology – Filariasis
Filariasis is a tropical parasitic disease caused by thread-like nematode worms of the superfamily Filarioidea. These parasites are transmitted to humans by insect vectors and may live in the lymphatic system, skin, connective tissue, serous cavities, or blood vessels. Adult worms can survive in the human host for more than 20 years, causing chronic disease and disability.
Filariasis includes several distinct syndromes. Lymphatic filariasis, caused by Wuchereria bancrofti, Brugia malayi, and Brugia timori, is endemic in many tropical and subtropical regions of Asia, Africa, South and Central America, and the Pacific. More than one billion people are at risk worldwide, with over 120 million infected and tens of millions suffering from disabling disease. Loiasis is confined mainly to the rainforests of western and central Africa. Onchocerciasis, or river blindness, affects millions in Africa and parts of South America and is a major cause of blindness. Dracunculiasis, or Guinea worm disease, occurs mainly in parts of Africa and Yemen. Dirofilariasis is rare in humans but has worldwide distribution, while mansonelliasis occurs in Africa, the Caribbean, and parts of Central and South America.
Major risk factors include living in or traveling to endemic areas and low socioeconomic status. Prevention depends on health education, vector control, and avoidance of insect bites. Recommended measures include sleeping under mosquito nets, wearing long sleeves, and using insect repellents containing at least 30% DEET. For dracunculiasis, prevention also includes drinking clean or filtered water, preventing infected individuals from entering water sources, and treating contaminated water to kill copepods.
The pathophysiology differs by species. In lymphatic filariasis, adult worms damage lymphatic vessels, causing dilation, valvular dysfunction, lymphatic obstruction, and eventually irreversible lymphedema and elephantiasis. In loiasis, larvae introduced by fly bites migrate beneath the skin, causing transient localized swelling known as Calabar swellings. In onchocerciasis, adult worms form nodules in the skin while microfilariae migrate through skin and eyes, causing dermatitis and blindness. In dracunculiasis, ingested larvae mature and female worms migrate to the skin, typically in the lower limbs, where they emerge through painful ulcers. Dirofilariasis often causes localized granulomatous reactions or pulmonary nodules. In mansonelliasis, dying worms provoke inflammatory responses leading to abscesses or granulomas.
The causative organisms include Wuchereria bancrofti, Brugia species, Loa loa, Onchocerca volvulus, Dracunculus medinensis, Dirofilaria species, and Mansonella species. Each is transmitted by a specific vector, such as mosquitoes, blackflies, midges, red tabanid flies, or infected copepods in water.
The clinical manifestations depend on the species involved. Lymphatic filariasis may cause fever, lymphangitis, lymphadenitis, hydroceles, lymphedema, elephantiasis, epididymitis, and occasionally bronchospasm. Loiasis presents with transient swellings, itching, hives, and migration of the worm across the eye. Onchocerciasis causes subcutaneous nodules, severe itching, skin thickening or pigment changes, lymphadenopathy, and visual loss. Dracunculiasis presents with painful skin ulcers from which the worm emerges. Dirofilariasis may cause cough, chest pain, or hemoptysis. Mansonelliasis may cause fever, swelling, rash, itching, headaches, arthralgia, and neurologic symptoms.
Physical examination findings vary accordingly. In lymphatic filariasis, patients may have lymphadenopathy, hydroceles, enlarged spermatic cord, lower extremity lymphedema, or even arthritis. Loiasis often shows visible Calabar swellings or worms migrating beneath the conjunctiva. Onchocerciasis produces characteristic skin changes and nodules, along with ocular disease. Dracunculiasis reveals a visible white worm emerging from an ulcer, usually on the lower extremity. Mansonelliasis may show pruritus, rash, edema, fever, hepatomegaly, and neurologic signs.
Diagnosis depends on the specific infection. Blood smears may reveal microfilariae in lymphatic filariasis or mansonelliasis. Skin snips or biopsies are useful in loiasis and onchocerciasis. Dracunculiasis is usually diagnosed clinically. Histology may be needed for dirofilariasis. Ultrasound can show adult worms in lymphatic vessels, and imaging such as CT or MRI may detect pulmonary nodules or deep skin nodules. Plain radiographs may reveal calcified Guinea worms.
Treatment depends on the species. In lymphatic filariasis, doxycycline is used to target Wolbachia endosymbionts, followed later by albendazole and ivermectin. Loiasis is treated with diethylcarbamazine. Onchocerciasis is treated with ivermectin, repeated after six months, with prednisone used beforehand if the eyes are involved. Dracunculiasis requires slow mechanical extraction of the worm, sometimes aided by metronidazole or mebendazole. Mansonella species are treated with albendazole or ivermectin depending on the species involved. There is no effective medical therapy for dirofilariasis. In general, treatment is more effective against microfilariae than adult worms, so repeated therapy may be necessary.
Supportive care and specialist referral are often needed. Infectious disease consultation may be helpful, and ophthalmologic assessment is essential in onchocerciasis. Surgical treatment may be required for removal of nodules in onchocerciasis or lung lesions in dirofilariasis. Hospitalization is mainly needed for complications such as septicemia from open wounds.
With timely diagnosis and treatment, disability and disfigurement can often be limited. However, complications can be severe, especially in lymphatic filariasis, where elephantiasis and secondary bacterial infection may occur, and in onchocerciasis, where blindness is a major consequence.
- Published on
Infectious Disease And Microbiology – Food-Borne Diseases
Food-borne diseases are illnesses that result from ingestion of food contaminated by pathogenic microorganisms, microbial toxins, or chemical substances. They are extremely common and represent a major public health problem. In the United States alone, it has been estimated that more than 75 million episodes occur annually. Outbreaks are most often caused by noroviruses, followed by Salmonella. Infants, older adults, and immunocompromised individuals are at particularly high risk for severe disease. Some pathogens also have specific risk groups; for example, Vibrio vulnificus infection is more common and more severe in patients with chronic liver disease or other forms of immunosuppression.
Prevention is centered on safe food handling and avoidance of high-risk foods. Raw or undercooked eggs, unpasteurized dairy products, raw or undercooked meat, poultry, and seafood, as well as soft cheeses, should be avoided when possible. Cross-contamination during food preparation should be prevented, and handwashing before handling food is essential. Vaccination also plays a role in prevention, particularly hepatitis A immunization and infant vaccination against rotavirus.
The causes of food-borne illness are broad and include bacterial, viral, parasitic, and noninfectious toxins. Bacterial causes include Salmonella, Shigella, enterohemorrhagic and enterotoxigenic Escherichia coli, Campylobacter jejuni, Vibrio species, Yersinia species, Clostridium perfringens, Staphylococcus aureus, Bacillus cereus, Clostridium botulinum, and Listeria monocytogenes. These organisms are associated with particular foods such as poultry, eggs, shellfish, contaminated water, undercooked beef, rice, canned foods, and unpasteurized dairy products. Viral agents include norovirus, rotavirus, and hepatitis A virus, while parasites include Giardia lamblia, Entamoeba histolytica, Cryptosporidium, and Cyclospora cayetanensis. Noninfectious causes include marine toxins such as ciguatera toxin, scombroid toxin, tetrodotoxin, shellfish toxins, as well as heavy metals, mushroom toxins, pesticides, and certain food additives such as monosodium glutamate.
The clinical presentation depends on the causative agent. Bacterial infections often present with diarrhea, abdominal cramps, fever, nausea, and vomiting, although the exact pattern varies. Salmonella commonly causes diarrhea, fever, and cramps, while Shigella often produces bloody, mucus-containing stools. Enterohemorrhagic E. coli typically causes severe abdominal pain and bloody diarrhea with little or no fever. Campylobacter may cause bloody diarrhea and fever, while cholera presents with profuse watery diarrhea leading to dehydration. Preformed toxin illnesses such as those caused by Staphylococcus aureus and the emetic type of Bacillus cereus produce abrupt, intense vomiting within hours of ingestion. Clostridium botulinum causes gastrointestinal symptoms followed by neurologic signs such as blurred vision, diplopia, dysphagia, and descending paralysis.
Viral food-borne diseases commonly cause acute gastroenteritis. Norovirus produces nausea, vomiting, cramping, diarrhea, low-grade fever, and myalgias, with vomiting more common in children and diarrhea more common in adults. Rotavirus causes vomiting and watery diarrhea, especially in young children. Hepatitis A has a much longer incubation period and presents with jaundice, dark urine, flu-like symptoms, and sometimes diarrhea.
Parasitic infections tend to have more prolonged courses. Giardia causes diarrhea, gas, and abdominal cramps that may last weeks to months. Entamoeba histolytica often causes bloody diarrhea and lower abdominal pain. Cryptosporidium usually causes watery diarrhea and cramps, while Cyclospora often causes prolonged watery diarrhea with nausea, anorexia, and weight loss.
Noninfectious food-borne toxins often produce rapid symptom onset. Ciguatera poisoning causes gastrointestinal symptoms followed by neurologic manifestations such as paresthesias and reversal of hot and cold sensation, and sometimes cardiovascular effects such as bradycardia and hypotension. Scombroid poisoning causes flushing, rash, urticaria, dizziness, and paresthesias shortly after eating affected fish. Tetrodotoxin from puffer fish causes rapid neurologic symptoms, ascending paralysis, and respiratory failure. Shellfish toxins may cause diarrheal, neurotoxic, amnesic, or paralytic syndromes depending on the toxin involved.
Physical examination usually focuses on assessing dehydration and abdominal findings. Signs such as dry mucous membranes, reduced urine output, tachycardia, and hypotension suggest volume depletion. Abdominal tenderness may be present. In Vibrio vulnificus infection, bullous skin lesions may occur.
Diagnosis depends on the suspected cause. Stool culture is useful for Salmonella, Shigella, Campylobacter, certain E. coli strains, Vibrio, and Yersinia, although special media are needed for some of these organisms. Clostridium botulinum diagnosis relies on testing stool, serum, or food for toxin. Viral illnesses such as norovirus are often diagnosed clinically, while rotavirus can be identified by stool immunoassay and hepatitis A by positive IgM antibody. Parasitic infections are diagnosed by stool examination for ova, cysts, or parasites, or by enzyme immunoassays. Toxin-mediated illnesses may require toxin assays, chromatography, or histamine detection in food.
Treatment for most food-borne illnesses is supportive, with fluid and electrolyte replacement as the mainstay. Specific antimicrobial therapy is reserved for selected infections. Typhoid fever caused by Salmonella typhi or S. paratyphi may be treated with cefixime, ceftriaxone, or quinolones, although resistance is an issue in some regions. Severe enterotoxigenic E. coli and Campylobacter infections may be treated with antibiotics. Cholera requires aggressive rehydration plus doxycycline or tetracycline in adults, or trimethoprim-sulfamethoxazole in young children. Botulism requires prompt antitoxin administration, with botulism immune globulin used in infants. Serious Listeria infections are treated with ampicillin, sometimes combined with gentamicin. Parasitic infections are treated with agents such as metronidazole, nitazoxanide, or trimethoprim-sulfamethoxazole depending on the organism. Noninfectious toxin syndromes are managed supportively, though antihistamines may help in scombroid poisoning and intravenous mannitol has been used for ciguatera.
The prognosis is generally good for most uncomplicated food-borne illnesses, though immunocompromised individuals may have prolonged disease and prolonged shedding of pathogens. Some conditions are life-threatening, especially cholera because of severe dehydration, and tetrodotoxin or paralytic shellfish toxin poisoning because of respiratory paralysis. Complications may also occur, such as temporary lactose intolerance after rotavirus infection, and reactive arthritis or Guillain–Barré syndrome after Campylobacter jejuni infection.
